Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / AstraZeneca===Durvalumab
Entity

AstraZeneca===Durvalumab

Tracked across 1 events · 9 articles · First seen Feb 05, 2026 · Last active Feb 23, 2026

Sentiment
20
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 20
Business
AIM ImmunoTech Rintatolimod Pancreatic Cancer Trial Milestones
AstraZeneca===Durvalumab (durvalumab) is AstraZeneca's anti-PD-L1 immune checkpoint inhibitor being combined with AIM ImmunoTech===Rintatolimod in the DURIPANC study for metastatic pancreatic cancer. Its inclusion in the study is part of a joint collaboration.
Feb 05, 2026 · 9 articles
NEWSDESK
Track AstraZeneca===Durvalumab live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.